Anavex Life Sciences Corp (AVXL)

[F1ash]

Studies and distilled clinical experience suggest:

"approximately 25% of patients taking cholinesterase inhibitors can be classified as ‘non-responders,’ experiencing clinical decline at the pre-treatment rate;

• approximately 25% of patients may be termed ‘super-responders’ with a significant and sustained improvement in function and cognition;

• the remaining patients may be expected to have modest improvement, or to be maintained at the same level without decline, over the first year of treatment.2,4"

http://www.stacommunications.com/journals/cme/2004/August/pdf/051.pdf


Unfortunately the time frame (a year?) is not specified.



Cholinesterase inhibitors do not often have a significant impact on cognitive tests, such as the Mini Mental Status Exam (MMSE). However, benefits may be seen in global ratings by patients or caregivers, improvements in activities of daily living (ADLs), or instrumental activities of daily living (IADLs), and reduction in behavioural disturbances due to the dementia.

So that last "bold" makes the whole thing clear as mud.